Background Male breast cancer has traditionally been compared with female breast cancer,
using the same staging system and prognostic indicators. A variety of histochemical and …

Background. Due to its rarity, male breast cancer (mBC) remains an inadequately
characterized disease, and current evidence for treatment derives from female breast cancer …

National Comprehensive Cancer Network (NCCN) guidelines for female breast cancer
treatment and surveillance are well established, but similar guidelines on male breast …

Between 1970 and 1998, 90 cases of male breast cancer with available pathological
material were retrieved. The disease often presented in aged patients (median? 66 years) …

Male breast cancer is rare, and experience of it in any single institution is limited. Our current
understanding regarding its biology, natural history, and treatment strategies has been …

BACKGROUND Although breast cancer in men is far less common than breast cancer in
women, it is associated with a less favorable prognosis. Conventional histopathologic …

Aim: To assess whether prognostic factors in male (MBC) and female (FBC) breast cancer
have similar impact on survival. Patients and Methods: Charts for men and women …

Compared with female breast cancer, male breast cancer is a rare disease, and the
relationship between clinical/pathologic features and prognosis is controversial, or even …

Studies concerning adjuvant systemic therapy and prognosis in male breast carcinoma
(MBC) are limited. We aimed to evaluate outcome of the changing practices of adjuvant …

We conducted an analysis on 41 cases of male breast cancer (median age 54 y; range 25–
82 y) in Kuwait. Most (51%) were stage II cancers with 65% arising in the left breast. There …